Signature Equity Partners’s Roivant Sciences ROIV Stock Holding History

Signature Equity Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.52K	Buy	+156	New	+$4.61K	﹤0.01%	969

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Signature Equity Partners's ROIV Position: Q2 2026 in Review

Signature Equity Partners opened a new position in Roivant Sciences (ROIV) in Q2 2026: 156 shares worth $5.52K. The stake represents ﹤0.01% of the portfolio and ranks #969 among its holdings.

498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Signature Equity Partners held 156 shares of Roivant Sciences worth $5.52K as of Q2 2026.
Roivant Sciences was a new Signature Equity Partners position in Q2 2026.
Roivant Sciences made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #969 holding.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.